SUMMARY
Albuterol extended-release tablets contain albuterol sulfate, the racemic form of albuterol and a relatively selective beta2-adrenergic bronchodilator, in an extended-release formulation.
Albuterol extended-release tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Albuterol Extended Release
Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. [2008.01.08] BACKGROUND: Albuterol is a beta-2 agonist that has been demonstrated to increase muscle strength in studies in animals and humans. Based on a pilot study of extended-release albuterol Repetabs in children with dystrophinopathies, the authors conducted a randomized, double-blind, placebo-controlled study with a crossover design... CONCLUSIONS: Short-term treatment with extended release albuterol may increase lean body mass, decrease fat mass, and improve functional measures in patients with dystrophinopathies. However, the significant change in strength of specific muscle groups found in the pilot study was not observed in the present study. These findings may be attributed to differences in the drug release and kinetics between Repetab and Volmax formulations as they affect the concentration of available beta-2 receptors on the muscle cell surface differently.
A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. [2006.11] Multiple studies have examined adding nebulized ipratropium bromide to intermittent albuterol for the treatment of acute asthma. Although continuous nebulized treatments in themselves offer benefits; few data exist regarding the efficacy of adding ipratropium bromide to a continuous nebulized system...
Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. [2006.08] The efficacy and safety of nebulized levalbuterol in adults with chronic obstructive pulmonary disease (COPD) was evaluated in this multicenter, randomized, double-blind, parallel design study. Randomized subjects (n = 209) received levalbuterol (LEV) 0.63 mg or 1.25 mg, racemic albuterol (RAC) 2.5 mg, or placebo (PBO) TID for 6 weeks...
Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. [2006.01] OBJECTIVE: A prospective blinded, randomized controlled trial was undertaken to compare the initial response of albuterol nebulized in heliox or control in the treatment of moderately severe asthma in children presenting to a pediatric ED... CONCLUSIONS: Our results demonstrate that albuterol nebulized with heliox offered no clinical benefit over standard therapy in the initial treatment of moderately severe asthma in the ED.
Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. [2004.03.23] The authors conducted a randomized, crossover, double-blind, placebo-controlled pilot study of albuterol in nine boys with dystrophinopathies. Primary outcomes were 1) isometric knee extensor and flexor strength; and 2) manual muscle testing (MMT)...
Clinical Trials Related to Albuterol Extended Release
Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate [Completed]
Preterm Infant Inhaled Albuterol Dosing [Recruiting]
The purpose of this study is to help determine the best dose of albuterol in premature
babies at risk of developing bronchopulmonary dysplasia (BPD). BPD is the chronic lung
disease of prematurity and is associated with increased morbidity and mortality, longer
hospital stays, and increased healthcare utilization. Albuterol is an inhaled medication
frequently used in premature infants with chronic lung disease and in people with asthma. It
is believed to be safe, but the optimal dose for infants is not clear. The investigators
hypothesize that albuterol may help a subset of premature infants with lung disease, but
they need to determine the best dose prior to doing research about how effective it is for
chronic lung disease/BPD. Response to each of three doses of albuterol will be measure using
pulmonary function tests.
Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients [Completed]
This is a multicenter, randomized, double-blind, double-dummy, placebo-controlled,
single-dose, 5-treatment, 5-period, 5-way crossover study in pediatric patients with
persistent asthma. The primary purpose of this study is to compare the efficacy and safety
of Albuterol Spiromax with that of ProAir HFA in pediatric asthma patients at 2 delivered
dose levels equivalent to 90 mcg and 180 mcg of albuterol base.
Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction [Terminated]
This clinical study will evaluate and establish the protective effects of Amphastar's
Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA), in preventing exercise-induced
bronchoconstriction (EIB) in adolescent and adult asthmatic patients, in comparison with (1)
Proventil®-HFA (Reference drug and Active Control ), and (2) Placebo-HFA control (HFA
propellant only). Safety of the test drug, Albuterol-HFA, will also be evaluated in
comparison to the Active and Placebo Controls. Analyses will be performed to determine if
the Armstrong's Albuterol-HFA has resulted in a significant bronchoprotective effect, with
attenuated Max % Fall in FEV1, in comparison to the Placebo-HFA control.
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics [Completed]
The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax®
versus placebo in subjects with persistent asthma.
|
|
Page last updated: 2008-03-26
|